Dyne Therapeutics (NASDAQ:DYN) Director Sells $209,148.00 in Stock

Dyne Therapeutics, Inc. (NASDAQ:DYN) Director Jason Rhodes sold 11,600 shares of the business’s stock in a transaction on Tuesday, May 5th. The stock was sold at an average price of $18.03, for a total transaction of $209,148.00. Following the completion of the sale, the director owned 8,390 shares in the company, valued at $151,271.70. This represents a 58.03% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Dyne Therapeutics Price Performance

DYN traded up $1.37 during trading hours on Wednesday, hitting $18.84. The company’s stock had a trading volume of 1,720,199 shares, compared to its average volume of 2,090,953. The business’s 50-day moving average price is $17.94 and its 200-day moving average price is $18.56. Dyne Therapeutics, Inc. has a 12 month low of $8.06 and a 12 month high of $25.00. The stock has a market cap of $3.11 billion, a price-to-earnings ratio of -5.32 and a beta of 1.08. The company has a current ratio of 22.25, a quick ratio of 22.25 and a debt-to-equity ratio of 0.15.

Dyne Therapeutics (NASDAQ:DYN) last announced its quarterly earnings results on Monday, March 2nd. The company reported ($0.76) earnings per share for the quarter, missing the consensus estimate of ($0.74) by ($0.02). Sell-side analysts expect that Dyne Therapeutics, Inc. will post -2.94 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the company. JPMorgan Chase & Co. increased its position in Dyne Therapeutics by 9.0% during the third quarter. JPMorgan Chase & Co. now owns 3,365,245 shares of the company’s stock valued at $42,570,000 after acquiring an additional 278,466 shares during the last quarter. Aberdeen Group plc increased its position in Dyne Therapeutics by 15.0% during the third quarter. Aberdeen Group plc now owns 556,733 shares of the company’s stock valued at $7,043,000 after acquiring an additional 72,770 shares during the last quarter. Vanguard Group Inc. increased its position in Dyne Therapeutics by 27.6% during the third quarter. Vanguard Group Inc. now owns 9,760,414 shares of the company’s stock valued at $123,469,000 after acquiring an additional 2,109,257 shares during the last quarter. Rafferty Asset Management LLC increased its position in Dyne Therapeutics by 93.4% during the third quarter. Rafferty Asset Management LLC now owns 213,211 shares of the company’s stock valued at $2,697,000 after acquiring an additional 102,963 shares during the last quarter. Finally, SG Americas Securities LLC bought a new position in Dyne Therapeutics during the fourth quarter valued at $5,191,000. Institutional investors own 96.68% of the company’s stock.

Analysts Set New Price Targets

Several brokerages recently weighed in on DYN. Weiss Ratings restated a “sell (d-)” rating on shares of Dyne Therapeutics in a research report on Monday, April 20th. HC Wainwright reduced their price target on shares of Dyne Therapeutics from $60.00 to $50.00 and set a “buy” rating on the stock in a research report on Tuesday, March 3rd. JPMorgan Chase & Co. reduced their price target on shares of Dyne Therapeutics from $17.00 to $16.00 and set a “neutral” rating on the stock in a research report on Tuesday, January 20th. Jefferies Financial Group restated a “buy” rating on shares of Dyne Therapeutics in a research report on Monday, March 9th. Finally, Wall Street Zen cut shares of Dyne Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Saturday. Three equities research analysts have rated the stock with a Strong Buy rating, eleven have given a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $35.14.

Dyne Therapeutics Company Profile

Dyne Therapeutics is a clinical-stage biotechnology company specializing in the development of localized gene regulation therapies for serious rare diseases. The company’s proprietary FORCE (Facilitated Orthogonal Receptor?mediated Cargo Evaluation) platform is designed to enable targeted delivery of oligonucleotide and gene therapy modalities to skeletal and respiratory muscles. Dyne’s lead programs focus on Duchenne muscular dystrophy (DMD), myotonic dystrophy type 1 (DM1) and facioscapulohumeral muscular dystrophy (FSHD), with preclinical and early clinical studies evaluating safety, tolerability and tissue specificity.

Since its founding in 2019 by Flagship Pioneering, Dyne has advanced multiple product candidates using its modular delivery approach, which couples engineered ligands with therapeutic payloads to improve uptake into muscle cells.